NO3061760T3 - - Google Patents
Info
- Publication number
- NO3061760T3 NO3061760T3 NO15185548A NO15185548A NO3061760T3 NO 3061760 T3 NO3061760 T3 NO 3061760T3 NO 15185548 A NO15185548 A NO 15185548A NO 15185548 A NO15185548 A NO 15185548A NO 3061760 T3 NO3061760 T3 NO 3061760T3
- Authority
- NO
- Norway
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
- C07D455/06—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine containing benzo [a] quinolizine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9789608P | 2008-09-18 | 2008-09-18 | |
| EP09820972.9A EP2326643B1 (en) | 2008-09-18 | 2009-09-18 | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| EP13160950.5A EP2610254B1 (en) | 2008-09-18 | 2009-09-18 | Deuterated benzoquinoline derivatives as inhibitors of vesicular monoamine transporter 2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO3061760T3 true NO3061760T3 (en:Method) | 2018-04-07 |
Family
ID=42107127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO15185548A NO3061760T3 (en:Method) | 2008-09-18 | 2009-09-18 |
Country Status (20)
| Country | Link |
|---|---|
| US (16) | US8524733B2 (en:Method) |
| EP (4) | EP2610254B1 (en:Method) |
| JP (3) | JP5616345B2 (en:Method) |
| CN (2) | CN102186848B (en:Method) |
| AU (1) | AU2009303758B8 (en:Method) |
| BR (1) | BRPI0913457B8 (en:Method) |
| CA (2) | CA2736409C (en:Method) |
| CY (1) | CY1120060T1 (en:Method) |
| DK (2) | DK3061760T3 (en:Method) |
| ES (4) | ES2896678T3 (en:Method) |
| HR (1) | HRP20180239T1 (en:Method) |
| HU (1) | HUE038158T2 (en:Method) |
| LT (1) | LT3061760T (en:Method) |
| NO (1) | NO3061760T3 (en:Method) |
| NZ (1) | NZ591615A (en:Method) |
| PL (1) | PL3061760T3 (en:Method) |
| PT (1) | PT3061760T (en:Method) |
| SI (1) | SI3061760T1 (en:Method) |
| SM (1) | SMT201800067T1 (en:Method) |
| WO (1) | WO2010044981A2 (en:Method) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO3061760T3 (en:Method) | 2008-09-18 | 2018-04-07 | ||
| WO2011058474A1 (en) * | 2009-11-10 | 2011-05-19 | Pfizer Inc. | N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| WO2011153157A2 (en) * | 2010-06-01 | 2011-12-08 | Auspex Pharmaceutical, Inc. | Benzoquinolone inhibitors of vmat2 |
| US9572880B2 (en) | 2010-08-27 | 2017-02-21 | Sienna Biopharmaceuticals, Inc. | Ultrasound delivery of nanoparticles |
| WO2012027728A2 (en) | 2010-08-27 | 2012-03-01 | Sienna Labs, Inc. | Compositions and methods for targeted thermomodulation |
| WO2012081031A1 (en) * | 2010-12-15 | 2012-06-21 | Enaltec Labs Pvt. Ltd. | Process for preparing tetrabenazine |
| CA2883641C (en) * | 2012-09-18 | 2021-09-14 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| US9550780B2 (en) | 2012-09-18 | 2017-01-24 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| RU2646809C2 (ru) | 2012-10-11 | 2018-03-07 | Нанокомпозикс, Инк. | Композиции серебряных нанопластин и способы |
| HK1219095A1 (zh) * | 2013-01-31 | 2017-03-24 | Auspex Pharmaceuticals, Inc. | Vmat2的benzoquinolone抑制剂 |
| US20160207917A1 (en) * | 2013-09-27 | 2016-07-21 | Auspex Pharmaceuticals, Inc. | Benzoquinolone inhibitors of vmat2 |
| WO2015077521A1 (en) * | 2013-11-22 | 2015-05-28 | Auspex Pharmaceuticals, Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| HK1224294A1 (zh) * | 2013-11-22 | 2017-08-18 | Auspex Pharmaceuticals, Inc. | 治疗异常肌肉活动的方法 |
| BR112016012747B1 (pt) | 2013-12-03 | 2022-07-12 | Auspex Pharmaceuticals, Inc | Processo de preparação de uma mistura racêmica de (rr,ss)-d6-tetrabenazina |
| MX2016009817A (es) * | 2014-01-27 | 2017-02-28 | Auspex Pharmaceuticals Inc | Inhibidores de benzoquinolina del transportador vesicular de monoaminas 2. |
| US10166183B2 (en) * | 2014-02-07 | 2019-01-01 | Auspex Pharmaceuticals, Inc. | Pharmaceutical formulations |
| CN106061506A (zh) | 2014-02-07 | 2016-10-26 | 纽罗克里生物科学有限公司 | 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途 |
| FI3936130T3 (fi) | 2014-05-06 | 2024-04-23 | Neurocrine Biosciences Inc | Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon |
| MA41557A (fr) * | 2015-02-18 | 2017-12-26 | Auspex Pharmaceuticals Inc | Inhibiteurs diméthoxyphényles du transporteur vésiculaire des monoamines 2 |
| CN114767672A (zh) * | 2015-03-06 | 2022-07-22 | 奥斯拜客斯制药有限公司 | 氘代丁苯那嗪或包含氘代丁苯那嗪的组合物 |
| WO2016154017A1 (en) * | 2015-03-20 | 2016-09-29 | Sienna Biopharmaceuticals, Inc. | Enhanced efficacy and targeted topical delivery of drugs to skin with nanoparticles |
| MY193767A (en) | 2015-10-30 | 2022-10-27 | Neurocrine Biosciences Inc | Valbenazine salts and polymorphs thereof |
| US10160757B2 (en) | 2015-12-23 | 2018-12-25 | Neuroscrine Biosciences, Inc. | Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
| US10479787B2 (en) | 2016-04-22 | 2019-11-19 | Lupin Limited | Process for preparation of tetrabenazine and deutetrabenazine |
| WO2017221169A1 (en) | 2016-06-24 | 2017-12-28 | Lupin Limited | Premixes of deutetrabenazine |
| CN107936008B (zh) * | 2016-10-13 | 2022-06-14 | 泰州华元医药科技有限公司 | 氘代化合物及其医药用途 |
| EP4400171A3 (en) | 2016-12-02 | 2024-09-11 | Neurocrine Biosciences, Inc. | Use of valbenazine for treating schizophrenia or schizoaffective disorder |
| US10703750B2 (en) | 2017-01-10 | 2020-07-07 | Sandoz Ag | Crystalline valbenazine free base |
| MX394415B (es) | 2017-01-27 | 2025-03-24 | Neurocrine Biosciences Inc | Metodos para la administracion de ciertos inhibidores de proteina transportadora transportador de monoamina vesicular-2 (vmat2). |
| CA3054238A1 (en) | 2017-02-27 | 2018-08-30 | Sandoz Ag | Crystalline forms of valbenazine salts |
| WO2018164996A1 (en) | 2017-03-06 | 2018-09-13 | Neurocrine Biosciences, Inc. | Dosing regimen for valbenazine |
| WO2018170214A1 (en) * | 2017-03-15 | 2018-09-20 | Zhang Chengzi | Analogs of deutetrabenazine, their preparation and use |
| JOP20190239A1 (ar) | 2017-04-19 | 2019-10-09 | Neurocrine Biosciences Inc | مركبات مثبطة لـ vmat2 وتركيبات منها |
| WO2018200605A1 (en) | 2017-04-26 | 2018-11-01 | Neurocrine Biosciences, Inc. | Use of valbenazine for treating levodopa-induced dyskinesia |
| IL309802A (en) | 2017-09-21 | 2024-02-01 | Neurocrine Biosciences Inc | High dose valbenazine formulation and related preparations, methods and kits |
| US10786495B2 (en) * | 2017-10-10 | 2020-09-29 | The Regents Of The University Of California | Vesicular monoamine transporter 2 inhibitors for treating stuttering |
| US20200230127A1 (en) | 2017-10-10 | 2020-07-23 | Neurocrine Biosciences, Inc. | Methods for the Administration of Certain VMAT2 Inhibitors |
| KR20250070134A (ko) | 2017-10-10 | 2025-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| WO2019130252A2 (en) * | 2017-12-29 | 2019-07-04 | Mylan Laboratories Ltd | Methods and intermediates for preparing deutetrabenazine |
| CN111655243A (zh) | 2018-01-29 | 2020-09-11 | 乔纳森·萨克纳-伯恩斯坦 | 在人类神经系统疾病中调节多巴胺的方法 |
| US11505549B2 (en) * | 2018-02-01 | 2022-11-22 | Lakshmi Prasad ALAPARTHI | Process for preparation of Deutetrabenazine |
| WO2019166962A1 (en) | 2018-03-01 | 2019-09-06 | Mylan Laboratories Ltd | Deutetrabenazine polymorphs and methods for their preparation |
| IL278185B2 (en) | 2018-04-25 | 2024-11-01 | Shinkei Therapeutics Inc | Tetrabenazine transdermal delivery device |
| CA3043075A1 (en) | 2018-05-14 | 2019-11-14 | Apotex Inc | Novel crystalline forms of benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| KR20210021006A (ko) | 2018-06-14 | 2021-02-24 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | Vmat2 억제제 화합물, 조성물 및 그와 관련된 방법 |
| CN108794337A (zh) * | 2018-07-10 | 2018-11-13 | 上海华堇生物技术有限责任公司 | 一种3,4-二羟基-β-硝基苯乙烯的新制备方法 |
| KR20210044817A (ko) | 2018-08-15 | 2021-04-23 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| US12152087B2 (en) | 2018-10-18 | 2024-11-26 | Oncopeptides Innovation Ab | Deuterated melflufen compounds |
| CA3123393A1 (en) * | 2018-12-13 | 2020-06-18 | Auspex Pharmaceuticals, Inc. | Deutetrabenazine for the treatment of dyskinesia in cerebral palsy |
| US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
| WO2021252741A1 (en) | 2020-06-10 | 2021-12-16 | Auspex Pharmaceuticals, Inc. | Osmotic dosage forms comprising deutetrabenazine and methods of use thereof |
| JP2023542676A (ja) | 2020-09-17 | 2023-10-11 | オースペックス ファーマシューティカルズ インコーポレイテッド | デューテトラベナジンを含む多粒子投薬形態 |
| CN116456970A (zh) | 2020-10-12 | 2023-07-18 | 奥斯佩克斯医药公司 | 包括氘代丁苯那嗪的胃滞留剂型 |
| AR125188A1 (es) | 2021-03-22 | 2023-06-21 | Neurocrine Biosciences Inc | Inhibidores del vmat2 y métodos de uso |
| IL309172A (en) | 2021-06-30 | 2024-02-01 | Neurocrine Biosciences Inc | Vulbanazine for use in the additional treatment of schizophrenia |
| US20240374528A1 (en) | 2021-09-17 | 2024-11-14 | Auspex Pharmaceuticals, Inc. | Multiparticulate dosage forms comprising deutetrabenazine |
| CA3242612A1 (en) | 2022-01-05 | 2023-07-13 | Terrence Joseph Connolly | Deuterium-enriched piperidinyl-methyl-purine amines and related compounds and their use in treating diseases and conditions |
| EP4489754A1 (en) | 2022-03-07 | 2025-01-15 | Neurocrine Biosciences, Inc. | Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the treatment of chorea associated with huntington's disease |
| KR20250019144A (ko) | 2022-06-08 | 2025-02-07 | 오스펙스 파마슈티칼스, 인코포레이티드 | 듀테트라베나진을 포함하는 삼투성 제형 및 이의 사용 방법 |
| WO2025038959A1 (en) | 2023-08-17 | 2025-02-20 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
| TW202521119A (zh) | 2023-08-17 | 2025-06-01 | 美商紐羅克里生物科學有限公司 | 用於投與特定vmat2抑制劑之方法 |
| WO2025096823A1 (en) | 2023-11-01 | 2025-05-08 | Neurocrine Biosciences, Inc. | Improvement, maintenance or reduction of decline of motor function associated with huntington disease using valbenazine |
| WO2025259267A1 (en) | 2024-06-11 | 2025-12-18 | Vector Vitale Ip Llc | Pharmaceutical compositions for modulating inflammation and oxidative stress comprising chemically enriched elements |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2830993A (en) * | 1958-04-15 | Quinolizine derivatives | ||
| US3045021A (en) | 1959-09-24 | 1962-07-17 | Hoffmann La Roche | Preparation of substituted 2-oxobenzoquinolizines |
| DE1253271B (de) * | 1961-03-28 | 1967-11-02 | Mta | Verfahren zur Herstellung von 2-Oxo-1, 2, 3, 4, 6, 7-hexahydro-11bH-benzo[a]chinolizinen |
| US4316897A (en) * | 1980-09-10 | 1982-02-23 | Hoffmann-La Roche Inc. | Method of lowering serum prolactin |
| US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| ES2293638T3 (es) * | 1994-03-25 | 2008-03-16 | Isotechnika, Inc. | Mejora de la eficacia de farmacos por deuteracion. |
| US6440710B1 (en) * | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
| ATE234299T1 (de) * | 1999-12-03 | 2003-03-15 | Pfizer Prod Inc | Sulfamoylheteroarylpyrazolverbindungen zur verwendung als analgetisches/entzündungshemmendes mittel |
| EP1134290A3 (en) * | 2000-03-14 | 2004-01-02 | Pfizer Products Inc. | Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors |
| TW200413273A (en) * | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| US20050153953A1 (en) * | 2003-11-21 | 2005-07-14 | Crista Trippodi-Murphy | Compositions and methods of treatment using L-type calcium channel blockers and cholinesterase inhibitors |
| GB2410947B (en) * | 2004-02-11 | 2008-09-17 | Cambridge Lab Ltd | Pharmaceutical compounds |
| WO2006053067A2 (en) | 2004-11-09 | 2006-05-18 | Prestwick Pharmaceuticals, Inc. | Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders |
| US7449458B2 (en) | 2005-01-19 | 2008-11-11 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| US20080033011A1 (en) * | 2005-07-29 | 2008-02-07 | Concert Pharmaceuticals Inc. | Novel benzo[d][1,3]-dioxol derivatives |
| US7750168B2 (en) * | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| BRPI0711481A8 (pt) | 2006-05-02 | 2017-11-28 | Univ Michigan Regents | derivados radiomarcados de dihidrotetrabenzeno e seu uso como agente de imagens |
| PT2081929E (pt) | 2006-11-08 | 2013-04-15 | Neurocrine Biosciences Inc | Compostos de 3-isobutil-9,10-dimetoxi- 1,3,4,6,7,11b-hexahidro-2h-pirido[2,1-a]isoquinolin- 2-ol substituídos e métodos com estes relacionados |
| CA2673137C (en) | 2006-11-21 | 2015-02-10 | Rigel Pharmaceuticals, Inc. | Prodrug salts of 2,4-pyrimidinediamine compounds and their uses |
| US20100204258A1 (en) * | 2007-03-12 | 2010-08-12 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for modulating insulin secretion and glucose metabolism |
| US8008500B2 (en) * | 2007-06-08 | 2011-08-30 | General Electric Company | Intermediates useful for making tetrabenazine compounds |
| US9827210B2 (en) * | 2007-06-29 | 2017-11-28 | Phovitreal Pty Ltd | Treatment or prophylaxis of a neurological or neuropsychiatric disorders via ocular administration |
| WO2009124357A1 (en) | 2008-04-10 | 2009-10-15 | Malvin Leonard Eutick | Fast dissolving oral formulations for critical drugs |
| GB2462611A (en) | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
| NO3061760T3 (en:Method) * | 2008-09-18 | 2018-04-07 | ||
| US20100113496A1 (en) * | 2008-09-25 | 2010-05-06 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of vmat2 |
| JP2013501810A (ja) | 2009-08-12 | 2013-01-17 | ヴァリーント インターナショナル（バルバドス）エスアールエル | 医薬組成物 |
| BR112012020585A2 (pt) | 2010-02-24 | 2018-04-17 | Auspex Pharmaceuticals Inc | composto, composição farmacêutica e método de tratamento de um distúrbio mediado por tirosina quinase |
| WO2011153157A2 (en) * | 2010-06-01 | 2011-12-08 | Auspex Pharmaceutical, Inc. | Benzoquinolone inhibitors of vmat2 |
-
2009
- 2009-09-18 NO NO15185548A patent/NO3061760T3/no unknown
- 2009-09-18 CA CA2736409A patent/CA2736409C/en active Active
- 2009-09-18 SM SM20180067T patent/SMT201800067T1/it unknown
- 2009-09-18 JP JP2011527995A patent/JP5616345B2/ja active Active
- 2009-09-18 HU HUE15185548A patent/HUE038158T2/hu unknown
- 2009-09-18 DK DK15185548.3T patent/DK3061760T3/en active
- 2009-09-18 ES ES17199778T patent/ES2896678T3/es active Active
- 2009-09-18 EP EP13160950.5A patent/EP2610254B1/en not_active Not-in-force
- 2009-09-18 US US12/562,621 patent/US8524733B2/en active Active
- 2009-09-18 LT LTEP15185548.3T patent/LT3061760T/lt unknown
- 2009-09-18 EP EP17199778.6A patent/EP3345905B1/en active Active
- 2009-09-18 AU AU2009303758A patent/AU2009303758B8/en active Active
- 2009-09-18 BR BRPI0913457A patent/BRPI0913457B8/pt active IP Right Grant
- 2009-09-18 DK DK09820972.9T patent/DK2326643T3/da active
- 2009-09-18 EP EP15185548.3A patent/EP3061760B1/en active Active
- 2009-09-18 ES ES13160950.5T patent/ES2563820T3/es active Active
- 2009-09-18 WO PCT/US2009/057480 patent/WO2010044981A2/en not_active Ceased
- 2009-09-18 SI SI200931797T patent/SI3061760T1/en unknown
- 2009-09-18 EP EP09820972.9A patent/EP2326643B1/en active Active
- 2009-09-18 CN CN200980141378.0A patent/CN102186848B/zh active Active
- 2009-09-18 PL PL15185548T patent/PL3061760T3/pl unknown
- 2009-09-18 CA CA2972242A patent/CA2972242A1/en not_active Abandoned
- 2009-09-18 PT PT151855483T patent/PT3061760T/pt unknown
- 2009-09-18 ES ES15185548.3T patent/ES2652289T3/es active Active
- 2009-09-18 NZ NZ591615A patent/NZ591615A/en unknown
- 2009-09-18 CN CN201410524867.7A patent/CN104311552A/zh active Pending
- 2009-09-18 ES ES09820972T patent/ES2425623T3/es active Active
-
2013
- 2013-07-03 US US13/934,960 patent/US20130296360A1/en not_active Abandoned
-
2014
- 2014-03-25 US US14/225,010 patent/US20140206713A1/en not_active Abandoned
- 2014-03-25 US US14/224,883 patent/US20140206712A1/en not_active Abandoned
- 2014-08-08 US US14/454,911 patent/US20140350044A1/en not_active Abandoned
- 2014-09-11 JP JP2014185634A patent/JP5970037B2/ja active Active
- 2014-10-15 US US14/515,047 patent/US20150080427A1/en not_active Abandoned
-
2015
- 2015-07-23 US US14/807,364 patent/US20150328207A1/en not_active Abandoned
-
2016
- 2016-02-11 US US15/041,571 patent/US20160158220A1/en not_active Abandoned
- 2016-04-08 US US15/094,517 patent/US20160220558A1/en not_active Abandoned
- 2016-07-08 JP JP2016136178A patent/JP6138322B2/ja active Active
- 2016-09-01 US US15/254,912 patent/US20160367548A1/en not_active Abandoned
- 2016-09-06 US US15/257,372 patent/US20160375005A1/en not_active Abandoned
-
2017
- 2017-02-28 US US15/445,402 patent/US20170166562A1/en not_active Abandoned
-
2018
- 2018-02-07 HR HRP20180239TT patent/HRP20180239T1/hr unknown
- 2018-02-07 CY CY20181100152T patent/CY1120060T1/el unknown
- 2018-12-05 US US16/210,077 patent/US20190375746A1/en not_active Abandoned
-
2020
- 2020-03-17 US US16/821,067 patent/US20200347048A1/en not_active Abandoned
-
2021
- 2021-11-05 US US17/519,922 patent/US20220267317A1/en not_active Abandoned
-
2025
- 2025-03-17 US US19/081,808 patent/US20250326747A1/en active Pending